ALKEM LABORATORIES LIMITED

Press Releases Alkem Laboratories Limited

Equities

ALKEM

INE540L01014

Delayed NSE India S.E. Other stock markets 03:29:16 2024-04-30 am EDT			5-day change	1st Jan Change
4,870 ^INR	-0.28%		+3.48%	-6.43%

Apr. 16	Alkem Laboratories Limited Receives A Demand Order Levying A Penalty of INR 35,099 State Tax Officer, Ghatak	CI
Mar. 28	Alkem Laboratories Forms Subsidiary for Medical Devices Business	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.	Feb. 12	AQ
Research Update Biosergen: Licensing deal with Alkem and CTA submission	Jan. 16	AQ
Biosergen's Partner Alkem Laboratories Submits Clinical Trial Application for First Patient Study with BSG005 in Invasive Fungal Infections in India as a Rescue Therapy	Dec. 12	AQ
Biosergen and Alkem Laboratories Ltd collaborates to develop anti-infective for severe fungal infections	23-09-25	AQ
Alkem Subsidiary Enzene Launches Adalimumab Biosimilar In India	23-03-10	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer